Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18649069 | 0.98 | FAAH (0.42) | FAAHCES1PPARATDP1L3MBTL1 | |
| SCHEMBL543465 | 0.98 | FAAH (0.42) | FAAHCES1PPARATDP1L3MBTL1 | |
| SCHEMBL15201267 | 0.98 | FAAH (0.42) | FAAHCES1PPARATDP1L3MBTL1 | |
| SCHEMBL11510236 | 0.98 | FAAH (0.42) | FAAHCES1PPARATDP1L3MBTL1 | |
| SCHEMBL7431163 | 0.98 | FAAH (0.42) | FAAHCES1PPARATDP1L3MBTL1 | |
| SCHEMBL10577731 | 0.98 | FAAH (0.42) | FAAHCES1PPARATDP1L3MBTL1 | |
| Fluoride SCHEMBL28689077 | 0.98 | FAAH (0.39) | FAAHCES1PPARATDP1L3MBTL1 | |
| Bromide SCHEMBL29849486 | 0.96 | FAAH (0.41) | FAAHCES1PPARATDP1L3MBTL1 | |
| SCHEMBL4595010 | 0.94 | — | — | |
| SCHEMBL13662366 | 0.88 | FAAH (0.56) | FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276311-B | Method for synthesizing aryl oxazole compound by using nickel complex as catalyst | 上海应用技术大学 | 2023-03-31 | — | — | CN | claimed |
| EP-4140484-A1 | COMPOSITIONS FOR TREATING OR PREVENTING VASOMOTOR SYMPTOMS | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-03-01 | — | — | EP | claimed |
| CN-115572258-A | C 2 Preparation method of axial chiral biquinoline framework compound | 中国科学院成都有机化学有限公司 | 2023-01-06 | — | — | CN | claimed |
| CN-114748624-A | Composition for treating or preventing vasomotor symptoms | 田边三菱制药株式会社 | 2022-07-15 | — | — | CN | claimed |
| CN-109879868-B | Preparation and application of pyrazole amide compound containing 2-aryl oxazole structure | 南通大学 | 2022-04-22 | — | — | CN | claimed |
| CN-114276311-A | Method for catalytically synthesizing aryl oxazole compound by using nickel complex | 上海应用技术大学 | 2022-04-05 | — | — | CN | claimed |
| CN-113384577-A | Composition for treating or preventing vasomotor symptoms | 田边三菱制药株式会社 | 2021-09-14 | — | — | CN | claimed |
| CN-107556262-B | Preparation method of 2-substituent arooxazole | 四川大学 | 2020-05-22 | — | — | CN | claimed |
| US-20190142821-A1 | COMPOSITIONS FOR TREATING OR PREVENTING VASOMOTOR SYMPTOMS | KALLYOPE, INC. | 2019-05-16 | — | — | US | claimed |
| EP-3468557-A1 | COMPOSITIONS FOR TREATING OR PREVENTING VASOMOTOR SYMPTOMS | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-04-17 | — | — | EP | claimed |
| WO-2003039558-A1 | 4' -O-SUBSTITUTED TYLOSIN ANALOGS | ENANTA PHARMACEUTICALS INC. (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2003011882-A1 | 4'-SUBSTITUTED LEUCOMYCINS | ENANTA PHARMACEUTICALS, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20020160966-A1 | BICYCLIC LEUCOMYCINS | SILICON VALLEY BANK DBA SILICON VALLEY EAST | 2002-10-31 | — | — | US | claimed |
| WO-2002081493-A1 | 9-AMINO-14-MEMBERED MACROLIDE DERIVED FROM LEUCOMYCIN | ENANTA PHARMACEUTICALS, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| US-6462026-B1 | ANTIBACTERIAL ACTIVITY TOWARD GRAM POSITIVE AND GRAM NEGATIVE BACTERIA AS WELL AS MACROLIDE RESISTANT GRAM POSITIVES | ENANTA PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | claimed |
| US-20020128212-A1 | 14-membered macrolides derived from leucomycins | SILICON VALLEY BANK DBA SILICON VALLEY EAST | 2002-09-12 | — | — | US | claimed |
| WO-2002066487-A1 | BYCYCLIC DERIVATIVES OF LEUCOMYCINS | ENANTA PHARMACEUTICALS, INC. (US) | 2002-08-29 | — | — | WO | claimed |
| US-6440942-B1 | MODIFICATIONS TO ENHANCE ACID STABILITY AND PREVENT ANHYDRO FORMATION; ROXITHROMYCIN AND CLARITHROMYCIN; ACTIVE AGAINST MLS-RESISTANT STRAINS (MLS=MACROLIDES-LINCOSAMIDES-STREPTOGRAMINES) | ENANTA PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | claimed |
| US-6436906-B1 | NOVEL MACROLIDES HAVING ANTIBACTERIAL ACTIVITY TOWARD GRAMPOSITIVE AND GRAMNEGATIVE BACTERIA AS WELL AS MACROLIDE RESISTANT GRAMPOSITIVES | ENANTA PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | claimed |
| WO-2002060912-A1 | 14-MEMBERED MACROLIDES DERIVED FROM LEUCOMYCINS | ENANTA PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160966-A1 | BICYCLIC LEUCOMYCINS | TLR5, SLC7A1, BCAT1 | FAAH 3419/4885CES1 3386/4885PPARA 2219/4885 |
| US-20190142821-A1 | COMPOSITIONS FOR TREATING OR PREVENTING VASOMOTOR SYMPTOMS | TRPM8, TRPM7, TRPM5 | FAAH 273/4885CES1 2252/4885PPARA 1045/4885 |
| US-20020128212-A1 | 14-membered macrolides derived from leucomycins | IL15, RPL21, RPL14 | FAAH 2539/4885CES1 1269/4885PPARA 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.